Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
4.700
-0.080 (-1.67%)
Oct 23, 2026, 3:04 PM CST
SHE:002581 Revenue
Shandong Sinobioway Biomedicine had revenue of 100.15M CNY in the quarter ending September 30, 2026, a decrease of -29.11%. This brings the company's total for the last twelve months to 256.94M, down -0.31% year-over-year. In the year 2025, Shandong Sinobioway Biomedicine had annual revenue of 274.81M, down -23.75%. That makes Shandong Sinobioway Biomedicine the 29,739th largest company in the world by revenue and 4,949th in China.
Revenue (ttm)
256.94M
Revenue Growth
-0.31%
P/S Ratio
12.07
Revenue / Employee
522.24K
Employees
492
Market Cap
3.10B
Revenue by Segment
- Biopharmaceutical 188.68M 68.7%
- Traditional Chinese Medicine Decoction Pieces Processing 83.07M 30.2%
- Pharmaceutical Distribution 2.99M 1.1%
- Unallocated Other 74.24K 0.0%
Fiscal year ended Dec 31, 2025 See the full SHE:002581 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 274.81M | -85.60M | -23.75% |
| Dec 31, 2024 | 360.41M | -69.39M | -16.14% |
| Dec 31, 2023 | 429.79M | 72.71M | 20.36% |
| Jan 1, 2023 | 357.08M | -45.63M | -11.33% |
| Jan 1, 2022 | 402.71M | 125.88M | 45.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Huaren Pharmaceutical | 1.30B |
| Qianjiang Yongan Pharmaceutical | 979.49M |
| Zhejiang Cheng Yi Pharmaceutical | 827.47M |
| Harbin Medisan Pharmaceutical | 805.09M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Tibet AIM Pharm. | 684.45M |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 433.31M |